Tucson, AZ – October 9, 2024 - Dr. Evan Unger, Executive Chairman of NuvOx Therapeutics (NuvOx), has been awarded the 2024 Harry Fischer Award by Contrast Media Research (CMR) in recognition of his exceptional contributions to the field of contrast media research. A commemorative medal was conferred at the annual CMR meeting in October in Oslo, Norway on October 7th, 2024.
Dr. Unger has been at the forefront of ultrasound contrast agent development since 1994. He pioneered the best-selling microbubble contrast agent, Perflutren, and continues to innovate at NuvOx by applying his expertise in microbubble technology to develop nanobubbles for oxygen delivery, the basis of NuvOx’s product, NanO2TM.
“Thank you to CMR for recognizing my life's work. I am honored to accept this award on behalf of my dedicated team. Their hard work and commitment have been the key to our success,” said Dr. Unger. “We have only scratched the surface of what is possible. I am thrilled to leverage my years of experience to advance microbubble and nanobubble technology.
“This award honors a long-term track record of outstanding research that has significantly shaped the field of contrast media. Specifically, Dr. Unger is recognized for his creative work towards the creation, thorough characterization and demonstration of the feasibility of ultrasound contrast agents in clinical practice”, says Dr. Jeff Bulte on behalf of CMR, who is a Professor of Radiology and Director of Cellular Imaging at the Johns Hopkins University School of Medicine.
Dr. Unger will redirect the monetary sum that comes with this award to support the travel of two junior trainees to attend the CMR meeting.
About Harry Fischer: Dr. Fischer was co-founder of CMR and a pioneer/innovator in the field of X-ray contrast media, clinical translation, safety and expansion of novel uses of contrast media that set the highest standards in the field.
About CMR: Contrast Media Research Symposium (CMR) was initiated by Elliot Lasser, San Diego, and Harry Fischer, Rochester, in 1970 and has had 22 subsequent editions. It has been and continues to be a unique gathering where top-level researchers from academia and the industry meet to exchange up-to-date thoughts and new data in a collegial and open symposium.
About NuvOx: NuvOx is a privately held clinical stage biopharmaceutical company developing a novel platform of oxygen therapeutics for the treatment of diseases where hypoxia plays a role. Hypoxia, or low oxygen, is responsible for resistance to cancer treatment, brain damage in stroke, and the death of COVID-19 patients with acute respiratory distress syndrome (ARDS).
The Company’s drug candidate- NanO2 represents a disruptive platform technology addressing multiple unmet needs, with positive results demonstrated in two completed Phase Ib/II studies: one in glioblastoma as a radiosensitizer and the other in stroke as a neuroprotectant. It was shown to be the most effective oxygen therapeutic among 74 clinical-stage compounds in literature review. It has safety and efficacy data in 7+ indications in various preclinical and clinical stages, including Orphan Drug Designation for both glioblastoma and sickle cell anemia.
The product can refer to safety data in ~2,000 subjects. The product is designed to be synergistic, rather than competitive with standard of care. The company also has a strong IP portfolio: 11 Patent Families; 11 issued US patents and 32 foreign equivalents.
NuvOx is conducting a Phase IIb clinical trial as a radiosensitizer in treatment of glioblastoma, and also plans to start a Phase IIb clinical trial for NanO2 in treatment of acute ischemic stroke, and a Phase Ib clinical trial for NanO2 in treatment of respiratory distress.
NuvOx Contact:
NuvOx PharmaRong Wang, President and CEO
Investor Contact:
Rong Wang
Forward looking statement
Certain statements in this release may constitute “forward-looking statements.” When used in this release, words like “may,” “will,” “can,” “should,” “expect,” “anticipate,” “believe,” “project,” or “intend” and other similar expressions are intended to identify forward-looking statements. Statements regarding future events and developments and future performance, as well as our expectations, beliefs, plans, or projections, are forward-looking statements which reflect only our predictions, assumptions, and estimates regarding future events and circumstances. Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Comments